Horizon Therapeutics Plc - HZNP STOCK NEWS

Horizon Therapeutics plc (Nasdaq: HZNP) announced participation in two upcoming virtual conferences. The Handelsbanken Life Science Innovation Day 2021 will be held on August 25, 2021, at 10 a.m. ET, followed by the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 10:15 a.m. ET. Both presentations will be webcast live and can be accessed via the company’s website. Horizon focuses on medicines for rare, autoimmune, and severe inflammatory diseases, aiming to transform lives through scientific expertise and compassion.

Horizon Therapeutics reported record Q2 2021 financial results, with net sales reaching $832.5 million, an 80% increase YoY. The company raised its full-year guidance for net sales and adjusted EBITDA, driven by strong demand for TEPEZZA, which saw sales of $453.3 million. The adjusted EBITDA for Q2 was $366.9 million, while GAAP net income was $158.1 million. Horizon also initiated three clinical trials and acquired a biologics manufacturing facility in Ireland. The company expects 2021 net sales to range between $3.025 billion and $3.125 billion, reflecting robust growth prospects.

Horizon Therapeutics plc (Nasdaq: HZNP) will release its second-quarter 2021 financial results on Aug. 4, 2021, at 8 a.m. Eastern Time. Following this announcement, management will conduct a live webcast to discuss financial and operational outcomes.

The webcast will be accessible via Horizon's investor relations website, where a replay will be available approximately two hours post-event.

Horizon Therapeutics plc (Nasdaq: HZNP) will host a **virtual R&D Day** for investors and analysts on **Sept. 29, 2021**, at **8 a.m. CT**. This event will feature presentations by the Company's R&D leadership and key opinion leaders, with a focus on Horizon’s **pipeline**. Details on accessing the live webcast will be shared closer to the date, and an archived version will be available shortly after. Horizon is dedicated to developing therapies for rare, autoimmune, and severe inflammatory diseases.

Horizon Therapeutics announced the enrollment of the first patient in a Phase 2 trial for HZN-7734, a fully human monoclonal antibody aimed at treating moderate to severely active systemic lupus erythematosus (SLE). The trial follows promising results from Phase 1b, where HZN-7734 demonstrated efficacy in decreasing plasmacytoid dendritic cells and reducing Type 1 Interferon. The primary endpoint is the change in the British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment after 48 weeks, aiming to provide better treatment options for SLE patients.

Horizon Therapeutics (Nasdaq: HZNP) is collaborating with Olympic gold medalist Gail Devers to raise awareness for Graves’ Disease Awareness Month this July. Devers, who has lived with Graves’ disease and Thyroid Eye Disease (TED) for over 30 years, aims to educate the public about the risks of TED, which affects up to half of those with Graves’. The initiative includes a new Listen to Your Eyes podcast series, educational videos, and a memory device to help individuals recognize TED symptoms early, emphasizing the importance of timely intervention.

Arrowhead Pharmaceuticals and Horizon Therapeutics have entered into a global collaboration for ARO-XDH, an investigational RNAi therapeutic for uncontrolled gout. Arrowhead will handle preclinical development, while Horizon will manage clinical development and commercialization. Arrowhead will receive $40 million upfront, with potential total milestone payments of up to $660 million plus royalties in the low- to mid-teens range on product sales. This partnership aims to address the unmet treatment needs in gout, affecting over nine million patients in the U.S.

Arrowhead Pharmaceuticals and Horizon Therapeutics have formed a global collaboration for ARO-XDH, an investigational RNA interference therapy aimed at treating uncontrolled gout. Under the agreement, Arrowhead will manage preclinical development, while Horizon will handle clinical development and commercialization. Arrowhead will receive an upfront payment of $40 million and could earn up to $660 million in milestones, plus royalties on sales. The partnership aims to address the significant unmet treatment needs in gout, affecting over nine million patients in the U.S.